- Home
- PYN vs MDAI Comparison
PYN vs MDAI Comparison
Compare PYN & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- MDAI
- Stock Information
- Founded
- PYN 2002
- MDAI 2013
- Country
- PYN United States
- MDAI United States
- Employees
- PYN N/A
- MDAI N/A
- Industry
- PYN Investment Managers
- MDAI Medical/Dental Instruments
- Sector
- PYN Finance
- MDAI Health Care
- Exchange
- PYN Nasdaq
- MDAI Nasdaq
- Market Cap
- PYN 34.5M
- MDAI 28.3M
- IPO Year
- PYN N/A
- MDAI N/A
- Fundamental
- Price
- PYN $5.74
- MDAI $1.96
- Analyst Decision
- PYN
- MDAI Strong Buy
- Analyst Count
- PYN 0
- MDAI 3
- Target Price
- PYN N/A
- MDAI $4.50
- AVG Volume (30 Days)
- PYN 19.9K
- MDAI 1.6M
- Earning Date
- PYN 01-01-0001
- MDAI 11-06-2024
- Dividend Yield
- PYN 5.07%
- MDAI N/A
- EPS Growth
- PYN N/A
- MDAI N/A
- EPS
- PYN N/A
- MDAI N/A
- Revenue
- PYN N/A
- MDAI $27,264,000.00
- Revenue This Year
- PYN N/A
- MDAI $61.78
- Revenue Next Year
- PYN N/A
- MDAI N/A
- P/E Ratio
- PYN N/A
- MDAI N/A
- Revenue Growth
- PYN N/A
- MDAI 44.52
- 52 Week Low
- PYN $4.84
- MDAI $0.82
- 52 Week High
- PYN $6.60
- MDAI $3.72
- Technical
- Relative Strength Index (RSI)
- PYN 46.37
- MDAI 44.95
- Support Level
- PYN $5.54
- MDAI $1.91
- Resistance Level
- PYN $5.79
- MDAI $2.24
- Average True Range (ATR)
- PYN 0.05
- MDAI 0.33
- MACD
- PYN 0.01
- MDAI -0.09
- Stochastic Oscillator
- PYN 80.00
- MDAI 3.73
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.